[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345090-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345090-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","synergistic-anticancer-effects-of-lenvatinib-combined-with-n-butylidenephthalide-in-human-colorectal-cancer-cells-research-paper","Synergistic Anticancer Effects of Lenvatinib Combined with N-butylidenephthalide in Human Colorectal Cancer Cells - Research Paper","","Colorectal cancer (CRC) remains a highly prevalent and lethal gastrointestinal malignancy, while lenvatinib—an inhibitor of multiple tyrosine kinases—has shown limited benefit as monotherapy. This study evaluates lenvatinib alone, N-butylidenephthalide (BP) alone, and their combination in HCT15 and HCT116 CRC cell lines. The combination displays synergistic cytotoxicity by promoting apoptosis through mitochondrial membrane potential disruption, increasing ROS accumulation, and triggering oxidative DNA damage via 8-OHdG induction.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/synergistic-anticancer-effects-of-lenvatinib-combined-with-n-butylidenephthalide-in-human-colorectal-cancer-cells-research-paper/345090/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/synergistic-anticancer-effects-of-lenvatinib-combined-with-n-butylidenephthalide-in-human-colorectal-cancer-cells-research-paper/345090.png","ImageObject",300,407,{"name":42,"@type":43},"Hazel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of combining lenvatinib with N-butylidenephthalide (BP) in CRC cells?","Question",{"text":63,"@type":64},"To determine whether the combination improves anticancer efficacy beyond each agent used alone, focusing on effects such as apoptosis and cell cycle regulation in HCT15 and HCT116 CRC cell lines.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the study assess cell proliferation, apoptosis, and reactive oxygen species (ROS) levels?",{"text":68,"@type":64},"Cell proliferation was measured by MTT assay, apoptosis by PI staining and annexin V-FITC staining followed by flow cytometry, and ROS levels by the DCFDA assay.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanism did the results identify for the combination’s anticancer effect?",{"text":72,"@type":64},"The combination promoted apoptosis by disrupting mitochondrial membrane potential, increased ROS accumulation leading to oxidative DNA damage via 8-OHdG induction, and induced G2/M arrest through modulation of the ATM-Chk2 signaling pathway.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345090,1790194619,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Ivyspring  \nInternational Publisher  \nInternationalJournal of Medical Sciences  \n2026; 23(4): 1356-1368. doi: 10.7150/ijms.122381  \nResearch Paper  \nSynergistic Anticancer Effects of Lenvatinib Combined with N-butylidenephthalide in Human Colorectal Cancer Cells  \nCheng-Chan Yu1,2,\\#, Sung-Ying Huang3,\\#, Shu-Fang Chang4, Yu-Hung Kuo4, Kuan-Fu Liao5, Sheng-Chun Chiu4,6,7,􀀍  \n1. Department of General Surgery, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan.  \n2. Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.  \n3. Department of Ophthalmology, Hsinchu Mackay Memorial Hospital, Hsinchu, Taiwan.  \n4. Department of Research, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan.  \n5. Division of Hepato-gastroenterology, Department of Internal Medicine, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan.  \n6. Department of Laboratory Medicine, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan.  \n7. Division of Basic Medical Sciences, College of Nursing, Tzu Chi University, Hualien, Taiwan.  \n\\#Cheng-Chan Yu and Sung-Ying Huang contributed equally to this article.  \n􀀍 Corresponding author: Sheng-Chun Chiu, Department of Research, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, 88, Section 1, Fengxing Road, Tanzi District, Taichung 42743, Taiwan; Tel: +886-4-36060666 ext:3430; Fax: +886-4-25385958; [E-Mail: honeyhopes@gmail.com](E-Mail: honeyhopes@gmail.com).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2025.07.24; Accepted: 2026.02.18; Published: 2026.03.04  \nAbstract  \nBackground: Colorectal cancer (CRC) is one of the most prevalent and deadly gastrointestinal malignancies worldwide. Lenvatinib, a multi-tyrosine kinase inhibitor, has shown limited clinical benefit asa monotherapy for CRC. Therefore, combining lenvatinib with N-butylidenephthalide (BP), a known anticancer and adjuvant agent, has been explored to enhance therapeutic outcomes. This study investigates the effects of lenvatinib and BP, individually and in combination, on HCT15 and HCT116 CRC cell lines.  \nMethods: Cell proliferation was assessed by MTT assay. Cell cycle distribution and apoptosis were measured with PI staining and annexin V-FITC staining, respectively, analyzed by flow cytometry. Reactive oxygen species (ROS) levels were determined using the DCFDA assay. Mitochondrial membrane potential (MMP) was evaluated with the JC-10 assay. Oxidative DNA damage was quantified by measuring 8-hydroxy-2’-deoxyguanosine (8-OHdG) levels using an ELISA kit. Immunofluorescence staining was performed to evaluate γ-H2AX foci expression. Protein expression levels related to apoptosis and cell cycle regulation were analyzed by western blotting.  \nResults: The combination of lenvatinib and BP exhibited synergistic cytotoxicity effect, promoting apoptosis by disrupting MMP in CRC cells. Additionally, this combination increased ROS accumulation, leading to oxidative DNA damage via 8-OHdG induction. Furthermore, the combination treatment induced G2/M phase cell cycle arrest by modulating the ATM-Chk2 signaling pathway.  \nConclusions: This study demonstrates that the combination of lenvatinib and BP represents a promising therapeutic strategy for CRC by enhancing apoptosis and cell cycle arrest through ROS-mediated DNA damage.  \nKeywords: colorectal cancer, lenvatinib, N-butylidenephthalide (BP), apoptosis, reactive oxygen species (ROS)  \nIntroduction  \nColorectal cancer (CRC) is the most prevalent gastrointestinal malignancy and the third leading  \ncause of cancer-related mortality worldwide [1] . The global incidence continues to rise","cbCainjFmOF6yA0e","https://ap.wps.com/l/cbCainjFmOF6yA0e","pdf",4645067,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What is the main purpose of combining lenvatinib with N-butylidenephthalide (BP) in CRC cells?\",\"answer\":\"To determine whether the combination improves anticancer efficacy beyond each agent used alone, focusing on effects such as apoptosis and cell cycle regulation in HCT15 and HCT116 CRC cell lines.\"},{\"question\":\"How did the study assess cell proliferation, apoptosis, and reactive oxygen species (ROS) levels?\",\"answer\":\"Cell proliferation was measured by MTT assay, apoptosis by PI staining and annexin V-FITC staining followed by flow cytometry, and ROS levels by the DCFDA assay.\"},{\"question\":\"What mechanism did the results identify for the combination’s anticancer effect?\",\"answer\":\"The combination promoted apoptosis by disrupting mitochondrial membrane potential, increased ROS accumulation leading to oxidative DNA damage via 8-OHdG induction, and induced G2/M arrest through modulation of the ATM-Chk2 signaling pathway.\"}]","Synergistic Anticancer Effects of Lenvatinib Combined with N-butylidenephthalide in Human Colorectal Cancer Cells - Research Paper | PDF",1790056488,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/335aac57fdbaae6a2c5edf474698f38e.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d4eb9d3e4c608a571c0f68dd6e61791.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac1ec1886510e34adb1570a1fbd4102a.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/281622445475118f663829d1f0ca6b7a.webp",980,1268]